Hepatitis B virus (HBV) X antigen (HBxAg) may contribute to the development of hepatocellular carcinoma (HCC) by activation of signalling pathways such as NF-kB. To identify NF-kB target genes differentially expressed in HBxAg-positive compared to -negative cells, HepG2 cells consistently expressing HBxAg (HepG2X cells) were stably transfected with pZeoSV2 or pZeoSV2-IkBa. mRNA from each culture was isolated and compared by PCR select cDNA subtraction. The results showed lower levels of a 2 -macroglobulin (a 2 -M) in HepG2X-pZeoSV2 compared to HepG2X-pZeoSV2-IkBa cells. This was confirmed by Northern and Western blotting, and by measurement of extracellular a 2 -M levels. Elevated transforming growth factor-b1 (TGF-b1) levels were also seen in HepG2X compared to control cells. Serum-free conditioned medium (SFCM) from HepG2X cells suppressed DNA synthesis in a TGF-b-sensitive cell line, Mv1Lu. The latter was reversed when the SFCM was pretreated with exogenous, activated a 2 -M or with anti-TGF-b. Since elevated TGF-b1 promotes the development of many tumour types, these observations suggest that the HBxAg-mediated alteration in TGF-b1 and a 2 -M production may contribute importantly to the pathogenesis of HCC.
INTRODUCTION
Chronic hepatitis B virus (HBV) infection may result in the development of liver diseases, including hepatitis, cirrhosis and hepatocellular carcinoma (HCC). There is increasing evidence that the HBV-encoded X antigen, HBxAg, contributes importantly to the development of HCC, although the mechanisms whereby it does so are incompletely understood (Feitelson, 1999) . HBxAg is a trans-activating protein that functions by binding to and altering the activity of transcription factors in the nuclei of infected cells and by constitutively activating a number of cytoplasmic signalling pathways (Henkler & Koshy, 1996; Feitelson, 1999) . Among the latter, HBxAg activates phosphorylation dependent signal transduction pathways involving Ras/Raf/ MAPK (Cross et al., 1993; Benn & Schneider, 1994; Natoli et al., 1995a) , diacylglycerol (DAG)/protein kinase C (PKC) (Cross et al., 1993; Kekule et al., 1993) , Jak1/STAT (Lee & Yun, 1998) and NF-kB (Su & Schneider, 1996) . The findings that NF-kB blocks hepatocellular apoptosis (Beg et al., 1995; Beg & Baltimore, 1996) , that HBxAg protects liver cells from apoptosis by inducing NF-kB , and that HCC is resistant to apoptosis (Natoli et al., 1995b) , suggest that HBxAg activation of NF-kB may play an important role in hepatocarcinogenesis.
Transforming growth factor-b1 (TGF-b1) is an important growth regulatory molecule that triggers apoptosis in hepatocytes (Gressner et al., 1997) . HCC is resistant to TGF-b1 even though the latter is transcriptionally upregulated in tumour cells, and TGF-b1 levels are commonly elevated in the sera of HCC patients (Ito et al., 1991; Song et al., 2002) . Under these circumstances, TGF-b1 may promote tumour growth, in part by killing or inhibiting the growth of surrounding hepatocytes. Some data suggest that the resistance of HCC to TGF-b1 is associated with mutation and loss of the receptor that mediates TGF-b1 signalling (Yamada et al., 1997) , although this has not been consistently observed (Wada et al., 1999) . Alternatively, HBxAg may suppress expression of the TGF-b1 type II receptor (Oshikawa et al., 1996) . Interestingly, the TGF-b1 gene is transcriptionally up-regulated by HBxAg (Yoo et al., 1996) , probably by the constitutive activation of transcriptional complexes containing Smad4 (Lee et al., 2001) , which mediates TGF-b1 signalling. TGF-b1 signalling also promotes the development of fibrosis and cirrhosis in patients with chronic liver disease (CLD) (Czaja et al., 1989) and in TGF-b1 transgenic mice (Sanderson et al., 1995) . These mice also develop HCC (Factor et al., 1997) . In other tumour types, elevated TGF-b1 stimulates angiogenesis, suppresses anti-tumour immune responses, promotes the development of drug resistance and enhances metastasis (Teicher, 2001) , through activation of the Smad and/or other signalling pathways that override apoptosis (Akhurst, 2002) . These observations suggest that the regulation of TGF-b1 activity may contribute importantly to the pathogenesis of HCC. a 2 -Macroglobulin (a 2 -M) is a broad-spectrum proteinase inhibitor in serum (Hall & Roberts, 1978; Sottrup-Jensen, 1989 ) that binds to many cytokines (Borth, 1992) , and in some cases, binding inactivates cytokine activity (Gonias et al., 1994) . In other cases, a 2 -M-protease and a 2 -Mcytokine complexes are rapidly cleared by endocytosis after binding to the LRP/a 2 -M receptor on hepatocytes, fibroblasts and macrophages (Williams et al., 1994) . Studies with a 2 -M gene knockout mice suggest that the primary function of a 2 -M in vivo may be to regulate the activities of cytokines in the TGF-b family (Umans et al., 1995; Webb et al., 1996) . In HCC, a 2 -M expression is decreased (Paradis et al., 2003) , although it is not clear whether part of the mechanism whereby HBxAg enhances TGF-b1 activity is through decreased expression of a 2 -M. Hence, experiments were designed to test the hypothesis that HBxAg up-regulated TGF-b1 activity was due not only to increased TGF-b1 production, but also to a decrease in a 2 -M expression.
METHODS
Cell lines and culture. The HepG2X (encoding HBx) and HepG2CAT (encoding bacterial chloramphenicol acetyltransferase) cells were made and characterized previously (Lian et al., 1999) . G418-resistant cultures were passaged by strandard trypsinization without selection of individual colonies, and the presence of HBxAg and CAT verified by Western blotting and standard CAT assay, respectively, as described (Lian et al., 1999) .
The TGF-b-sensitive cell line, Mv1Lu (mink lung epithelial cell line; ATCC, CCL-64), was cultured in the same growth medium as HepG2 cells.
Stable transfection of HepG2X cells with pZeoSV2-IkBa-HA.
Separate cultures of HepG2X and HepG2CAT cells were stably transfected with pZeoSV2-IkBa-HA or pZeoSV2 vector, as described . Cells were selected in zeocin for 4 weeks. Exogenous IkBa expression was detected by Western blotting using anti-HA as the primary antibody . NF-kB activity was measured in a luciferase assay by transient transfection of cells with the reporter plasmid pGL2-HIV-LTR-1. In this plasmid, luciferase expression was under control of the HIV LTR-1 promoter, which contained an NF-kB binding site that is responsive to HBxAg (Twu et al., 1989; Pan et al., 2001) .
PCR select cDNA subtraction, cloning and sequencing. mRNA was isolated from HepG2X-pZeoSV2 and HepG2X-pZeoSV2-IkBa cells (see below), reverse transcribed to cDNA fragments with random primers, and then subjected to PCR select cDNA subtraction (BD Biosciences/Clontech), as described (Lian et al., 1999) . The cDNA fragments obtained from subtraction were then individually cloned into pT7BlueT vector (Novagen). DNA sequencing was performed at the sequencing facility on campus. The sequences obtained were compared to those in GenBank by GCG software for homology to known genes.
Northern blot analysis. Total RNA from HepG2CAT-pZeoSV2, HepG2X-pZeoSV2 and HepG2X-pZeoSV2-IkBa cells was isolated using the RNeasy Mini Kit (Qiagen). Ten mg of total RNA from each culture was analysed by formaldehyde denaturing agarose gel electrophoresis. The a 2 -M cDNA fragment identified from subtraction was labelled with [a-32 P]dCTP using the Prime-a-Gene Labelling system (Promega) for use as a probe. A G3PDH probe was used to normalize for RNA loading in each sample.
Western blot analysis. HepG2CAT-pZeoSV2, HepG2X-pZeoSV2 and HepG2X-pZeoSV2-IkBa cells were treated with lysis buffer containing 50 mM Tris/HCl (pH 7?4), 250 mM NaCl, 5 mM EDTA, phosphatase inhibitors (50 mM NaF, 0?1 mM Na 3 VO 4 ), protease inhibitors (1 mM PMSF, 10 mg leupeptin ml 21 , 10 mg pepstatin ml
21
) and 1 % Triton X-100 for 15 min on ice. Forty mg of total protein in each sample was reduced in 10 % 2-mercaptoethanol, and analysed by SDS-PAGE on 4-20 % gradient gels. Proteins were then blotted onto PVDF membranes (Millipore) and then blocked overnight in PBS containing 5 % nonfat milk. For primary antibody, rabbit anti-human a 2 -M polyclonal antibody (A749/R5H, Accurate Chemical Co., Westbury, NY, USA) was used at a 1 : 2000 dilution. Mouse anti-human b-actin monoclonal antibody (Clone AC-15, Sigma) was used at 1 : 5000 as an internal control. For secondary antibodies, horseradish peroxidase (HRP)-conjugated goat antirabbit Ig (1 : 10 000 dilution) or HRP-conjugated goat anti-mouse Ig (1 : 3000 dilution) (Accurate) was used. The results were visualized using the ECL detection system (Amersham).
Immunoprecipitation of a 2 -M in culture medium from metabolically labelled cells. Five-million HepG2CAT-pZeoSV2, HepG2X-pZeoSV2 or HepG2X-pZeoSV2-IkBa cells in 100 mm dishes were incubated for 16 h in complete medium. After each culture had been washed twice with PBS, the cells were incubated with methionine-free medium containing 5 % dialysed FCS for 1 h, which was then replaced with 4 ml of the same medium containing 70 mCi [
35 S]methionine (NEN) ml 21 for 16 h. Cell supernatants were collected through a 0?45 mm filter to remove cell debris, and 1?2 ml of each sample was used for immunoprecipitation. All immunoprecipitation steps were done at 4 uC. Samples precleared with protein A-agarose beads were incubated with 15 ml of rabbit anti-human a 2 -M for 3 h, and then with 20 ml of protein A-agarose beads overnight. Beads were collected and washed four times with NP-40 buffer (150 mM NaCl, 50 mM Tris/HCl, pH 6?8, 1 % NP40) by centrifuging at 4000 r.p.m. for 5 min each time. Finally, samples were analysed by SDS-PAGE on 7?5 % gels, and results visualized by autoradiography.
Preparation of serum-free conditioned medium (SFCM). Cells were seeded in 100 mm dishes (4610 6 cells per dish) in complete medium. The next day, the cultures were washed twice with PBS, and then incubated overnight in serum-free Eagle's MEM containing 0?02 % BSA. Cells were then incubated in fresh serum-free medium for an additional 24 h. Cell culture supernatants were collected, filtered, aliquoted and stored at 280 uC until use.
DNA synthesis. To activate TGF-b in SFCM, the pH was adjusted to 1?5 with HCl. Samples were incubated at room temperature for 15 min, and then neutralized with NaOH/HEPES to pH 7?4-7?5. Activated SFCM was diluted to 75 % with fresh serum-free medium (to allow for addition of other reagents) for DNA synthesis assays. In some experiments, 75 % SFCM was incubated with 10 mg TGF-b antibody ml 21 (clone 1D11, which binds all TGF-b isoforms; R & D Systems) for 1 h at 37 uC prior to evaluation in the DNA synthesis assay. Mouse IgG (Sigma) was used as a control in place of TGF-b antibody. In other experiments, 75 % SFCM was incubated with methylamine-treated a 2 -M (a 2 -M-MA) (BioMac, Leipzig, Germany) at 37 uC for 2 h. Methylamine treatment transforms (activates) nearly 100 % of a 2 -M, which was confirmed by the faster migration of the activated form in Rate (native)-PAGE (data not shown).
The Mv1Lu cells were seeded in 96-well plates (1610 4 cells per well) in complete medium for 24 h. Medium was changed to 75 % of activated SFCM with or without TGF-b neutralizing antibody, and with or without a 2 -M-MA. After incubation for 18 h at 37 uC, [ 3 H]thymidine (1 mCi per well) was added for an additional 7 h. Cells in each well were harvested onto glass fibre filters using a cell harvester and the radioactivity incorporated in DNA was determined by scintillation counting. Each experiment was done in quadruplicate.
Determination of TGF-b1, -b2 and a 2 -M levels in SFCM.
TGF-b1, -b2 and a 2 -M levels in SFCM were determined by ELISAs for each antigen. ELISA kits for human TGF-b1 (Quantikine kit) and TGF-b2 (Quantikine kit) were obtained from R&D Systems. a 2 -M was determined by 'sandwich' ELISA. Rabbit anti-human a 2 -M (IgG fraction) was used as capture antibody and affinitypurified HRP-conjugated goat anti-human a 2 -M (Accurate) used as detection antibody. Purified human a 2 -M (Sigma) was used to create a standard curve for each experiment. All samples were tested in duplicate.
Statistics. Student's t-test was used to evaluate (1) the mean levels of DNA synthesis in Mv1Lu cells treated with 75 % SFCM from different sources; (2) the significance of mean levels of NF-kB activity, as measured by luciferase levels, in transiently transfected cells; (3) the mean levels of a 2 -M and TGF-b1 in SFCM; and (4) the relative levels of a 2 -M mRNA and protein in differently treated cells. A significant result is when P<0?05.
RESULTS

Introduction of exogenous IkBa into HepG2X cells
The findings that HBxAg stimulates NF-kB (Su & Schneider, 1996) , that NF-kB is hepatoprotective (Beg et al., 1995) , in part, by inhibiting apoptosis (Beg & Baltimore, 1996) , that HBxAg confers resistance to apoptosis in a number of cell lines tested (Shih et al., 2000; Pan et al., 2001) , and that an important characteristic of HCC is its resistance to apoptosis (Natoli et al., 1995b) , suggest that the constitutive activation of NF-kB in HBxAg-positive cells may contribute importantly to hepatocarcinogenesis. To examine this in more detail, HepG2X cells (Lian et al., 1999) were stably transfected with pZeoSV2 or pZeoSV2-IkBa . Following selection in zeocin, exogenous IkBa expression was demonstrated by Western blotting, and suppressed NF-kB activity in a transient luciferase reporter gene assay with HepG2X cells ).
Identification and verification of a 2 -M as a gene down-regulated in HepG2X-pZeoSV compared to HepG2X-pZeoSV-IkBa cells To discern differences in gene expression triggered by NFkB in HepG2X cells, PCR select cDNA subtraction was performed with whole cell mRNA isolated from HepG2X-pZeoSV2 and HepG2X-pZeoSV2-IkBa cells. The results yielded three cDNA fragments that may represent differentially expressed genes. Among the two up-regulated genes, one consisted of a 792 bp fragment that had 99?4 % homology over 621 bp with the human fibronectin gene (GenBank accession no. A14133), which encodes an important extracellular matrix component of the fibrogenic response. The other up-regulated gene consisted of a 540 bp fragment that was 98?9 % homologous over a 444 bp overlap with a human fetal liver cDNA clone (GenBank accession no. H49417). Cloning and expression of the full-length cDNA from the latter, referred to as up-regulated gene 7 (URG7), is stimulated nearly 5-fold in HepG2X cells. HBxAg blocks anti-Fas-mediated apoptosis in HepG2 cells, and it was found that most of this was due to the NF-kB-dependent expression of URG7 (Lian et al., 2001) . Sequence analysis of the cDNA fragment that was strongly down-regulated in HepG2X-pZeoSV2 cells compared to HepG2X-pZeoSV2-IkBa cells showed 100 % homology over a 500 bp region with human a 2 -M cDNA when compared to entries in GenBank (Benson et al., 1997) . This fragment, spanning nucleotides 3026-3525, based upon GenBank accession no. A21185, was used as a probe for further studies. To verify the results of subtractive hybridization, Northern blotting was performed with RNA isolated from the cells used for PCR select cDNA subtraction. The results show that the levels of a 2 -M RNA in HepG2X-pZeoSV2-IkBa cells were 4?7-fold higher than in HepG2X-pZeoSV2 cells following normalization with G3PDH. In comparison, the levels of a 2 -M mRNA in HepG2CAT-pZeoSV2 control cells were 6?9-fold higher than in HepG2X-pZeoSV2 cells (Fig. 1a) . Western blotting for a 2 -M yielded similar results following normalization to b-actin (Fig. 1b) . Hence, HepG2X-pZeoSV2 cells had depressed levels of a 2 -M expression relative to HepG2CAT-pZeoSV2 cells, and the introduction of exogenous IkBa to HepG2X cells restored from about half to two-thirds of the a 2 -M levels in HepG2X-pZeoSV2 compared to control cells (HepG2CAT-pZeoSV2). These results suggest that HBxAg suppresses a 2 -M gene expression. Although this suppression may be at the transcriptional level and/or effect a 2 -M mRNA stability, it appears to be NF-kB dependent.
HBxAg suppresses accumulation of extracellular a 2 -M
Since extracellular a 2 -M binds to and inactivates TGF-b, it was important to see whether the suppression of a 2 -M expression in HBxAg-positive HepG2 cells also resulted in decreased accumulation of a 2 -M in the tissue culture supernatant. Accordingly, HepG2CAT-pZeoSV2, HepG2X-pZeoSV2 and HepG2X-pZeoSV2-IkBa cells were radiolabelled with [
35 S]methionine. Equal volumes of tissue culture supernatants were immunoprecipitated with anti-human a 2 -M, and then analysed by SDS-PAGE and autoradiography. The results showed that there was 7?7-fold more a 2 -M in the supernatant of HepG2CAT-pZeoSV2 cells (Fig. 2, lane 1) compared to that of HepG2X-pZeoSV2 cells (P<0?001) (Fig. 2, lane 2) . In comparison, the amount of a 2 -M recovered from the supernatants of HepG2X-pZeoSV2-IkBa cells (Fig. 2, lane 3) was approximately 4-fold higher than the levels observed in HepG2X-pZeoSV2 supernatants (P<0?003). Immunoprecipitation of the supernatant from HepG2CAT-pZeoSV2 cells with normal IgG resulted in no discernable band (Fig. 2, lane 4) , demonstrating that the immunoprecipitations were specific. These results suggest that the decreased levels of a 2 -M within HepG2X cells were also decreased in the supernatant from the same cultures, and that a significant fraction of the a 2 -M could be recovered when HepG2X cells were stably transfected with pZeoSV2-IkBa.
HBxAg up-regulates TGF-b1 in HepG2 cells
Given that TGF-b1 is transcriptionally activated by HBxAg (Yoo et al., 1996; Lee et al., 2001) , the levels of TGF-b1 were assayed by quantitative ELISA in SFCM from HepG2X-pZeoSV2, HepG2X-pZeoSV2-IkBa and HepG2CAT-pZeoSV2 cells. In SFCM from HepG2CAT-pZeoSV2 cells, the levels of TGFb1 were some 7-to 8-fold lower than the SFCM from HepG2X-pZeoSV2 (P<0?001) and HepG2X-pZeoSV2-IkBa cells (Fig. 3) . As expected, when extracellular a 2 -M was assayed by ELISA, the levels were highest in SFCM of HepG2CAT-pZeoSV2 cells, about 7-fold lower in the SFCM from HepG2X-pZeoSV2 cells (P<0?001), but less than 2-fold reduced in the SFCM from HepG2X-pZeoSV2-IkBa cells (Fig. 3) . TGF-b2, also assayed by ELISA, was not detectable in any of the SFCM, suggesting HBxAg alters only TGF-b1 but not TGF-b2 expression. Hence, TGF-b1 expression is up-regulated in the supernatants of HBxAg-positive cells, but its increased production, unlike that of a 2 -M, is not NF-kB dependent.
When the a 2 -M : TGF-b1 ratio was determined on a molar basis in the SFCM of HepG2CAT-pZeoSV2 cells (Fig. 3) , it was about 1440, while for HepG2X-pZeoSV2 cells it was 29. The ratio of these numbers showed that the introduction of HBxAg into HepG2 cells resulted in an almost 50-fold change in the relative amounts of a 2 -M and TGF-b1 in the SFCM. The question now became, what were the functional consequences of this altered a 2 -M : TGF-b1 ratio?
Decreased a 2 -M : TGF-b1 ratio was associated with increased TGF-b activity
To determine whether there is a net difference in TGF-b activity in HBxAg-positive compared to -negative HepG2 cells, SFCM from HepG2CAT-pZeoSV2 or HepG2X-pZeoSV2 ]thymidine uptake) in this cell line is very sensitive to inhibition by TGF-b. In this assay, acidification followed by neutralization of the SFCM was performed in order to activate TGF-b. Accordingly, when this experiment was done with serum-free medium, which contained no TGF-b, high levels of DNA synthesis were observed (Fig. 4, group  1) . When unacidified SFCM from HepG2CAT-pZeoSV2 or HepG2X-pZeoSV2 was tested, no inhibition of DNA synthesis was observed (Fig. 4, group 1) , since all of the TGF-b in unacidified SFCM was inactive. In group 2, in which TGF-b was activated, serum-free medium again showed no inhibition of DNA synthesis. In contrast, there was about a 3?5-fold inhibition of [ 3 H]thymidine incorporation when SFCM from HepG2CAT-pZeoSV2 cells was tested (white bar), while a 15-to 18-fold decrease in proliferation was observed when the assay was repeated with SFCM from HepG2X-pZeoSV2 cells. Each of these differences was highly significant compared to the values for serum-free medium alone (P<0?001). Comparison of the inhibitory activities of SFCM from HepG2CAT-pZeoSV2 and HepG2X-pZeoSV2 showed that the latter inhibited 5-to 6-fold more than the former (P<0?001) (Fig. 4, group 2) . To determine whether inhibition of DNA synthesis was related to TGF-b activity, the SFCM samples from group 2 were preincubated with normal IgG, which had no effect upon the inhibition of DNA synthesis (Fig. 4,  group 3) , or with anti-human TGF-b (Fig. 4, group 4) , which completely reversed the inhibitory effect of the SFCM samples. These results suggest that the HBxAgmediated increase in expression of TGFb (and suppression of a 2 -M expression) resulted in a stronger inhibition of DNA synthesis on Mv1Lu reporter cells compared to the same experiment done with SFCM isolated from HBxAgnegative HepG2 cells, and that all of the inhibition observed in this assay was due to TGF-b.
Exogenous a 2 -M blocks the TGF-b1 inhibition of DNA synthesis in SFCM If in natural HBV infections the levels of a 2 -M in serum regulate the activity of TGF-b1, then addition of exogenous activated (methylamine-reated) a 2 -M or a 2 -M-MA to SFCM from HepG2X-pZeoSV2 cells should inactivate the TGF-b1 and relieve the inhibition of DNA synthesis in Mv1Lu. When this experiment was done, the SFCM from HepG2X-pZeoSV2 cells significantly inhibited proliferation relative to the SFCM from HepG2CAT-pZeoSV2 cells (P<0?001) (Fig. 5) , as expected. However, when the amount of exogenous a 2 -M-MA added to the SFCM from HepG2X-pZeoSV2 cells was increased to levels similar to that found in normal human serum (which is in the mg % range) (LaMarre et al., 1991), TGF-b1 activity was blocked, and control levels of DNA synthesis were observed (Fig. 5) . These observations show that the inhibitory effects of TGF-b1 on DNA synthesis are reversible in the presence of activated a 2 -M.
DISCUSSION
The observations that HBxAg activates NF-kB (Henkler & Koshy, 1996; Su & Schneider, 1996) , that NF-kB is hepatoprotective (Beg et al., 1995) , in part, by blocking apoptosis (Beg & Baltimore, 1996) , and that HBxAg inhibits both Fas and TGF-b1 triggered apoptosis (Shih et al., 2000; Pan et al., 2001) , suggest that the constitutive activation of NF-kB by HBxAg may contribute importantly to the development of preneoplastic foci and HCC. Using PCR select cDNA subtraction, this study revealed that HBxAg suppressed the expression of a 2 -M, which is known to bind to and inactivate TGF-b. In fact, a 2 -M is a major negative MV1LU cells were incubated with serum-free medium (grey bars), SFCM from HepG2CAT-pZeoSV2 cells (white bars) or SFCM from HepG2X-pSV2zeo cells (black bars). Test medium was added to the reporter cell line unacidified (group 1), acidified and neutralized (group 2), acidified, neutralized and preincubated with normal IgG (10 mg ml "1 ) (group 3), or acidified, neutralized and preincubated with anti-TGF-b (10 mg ml "1 ) (group 4). The data presented are means of three experiments, each done in triplicate. regulatory factor for the TGF-b family of proteins (LaMarre et al., 1991; Gonias et al., 1994; Webb et al., 1996 Webb et al., , 1998 . a 2 -M expression was suppressed 5-to 6-fold in HepG2X-pZeoSV2 compared to HepG2CAT-pZeoSV2 cells (Figs 1  and 2 ). Similar differences were observed in SFCM from these cells (Fig. 3) , while TGF-b1 expression increased 7-to 8-fold (Fig. 3) . This resulted in a significant increase in the TGF-b1 DNA synthesis inhibitory activity in a reporter cell line (Fig. 4) . Therefore, HBxAg increases TGF-b1 signalling through trans-activating the TGF-b1 gene (Yoo et al., 1996) , by stimulating Smad4 (which mediates TGF-b1) signalling (Lee et al., 2001) and by reducing expression of the major TGF-b1 inhibitor, a 2 -M (this study). The latter is likely to be another mechanism whereby HBxAg promotes TGF-b1 activity during CLD.
TGF-b1 is elevated in the blood of HBV carriers with HCC (Castilla et al., 1991; Ito et al., 1991; Song et al., 2002) , while a recent microarray-based study demonstrated a consistent suppression of a 2 -M gene expression in HCC (Paradis et al., 2003) . a 2 -M gene expression is also reportedly reduced or absent in several human hepatoma cell lines (Kondo et al., 1998) . Hence, the observations made here are consistent with those of increased TGF-b1 and decreased a 2 -M made in clinical studies. Collectively, these observations suggest that the increase in TGF-b1 and decrease in a 2 -M by HBxAg parallels the shift in expression of these proteins in vivo. Moreover, a 2 -M gene expression has been reported to be depressed in adenocarcinomas and squamous cell carcinomas of the lung (McDoniels-Silvers et al., 2002) , suggesting that the phenomenon observed here may occur in other tumour types, although by other mechanisms.
The impact of a 2 -M expression levels in HepG2 cells upon TGF-b1 activity was measured using a [ 3 H]thymidine incorporation assay in a mink lung epithelial cell line that is highly sensitive to the inhibitory effects of TGF-b1 upon DNA synthesis. The results in Fig. 4 show that the TGF-b1 levels in the SFCM from HepG2CAT-pZeoSV2 cells clearly inhibited DNA synthesis compared to serum-free medium, but that when SFCM from HepG2X-pZeoSV2 cells was used, the inhibition was significantly greater, suggesting that altered a 2 -M : TGF-b1 ratios in the supernatants of HepG2X-pZeoSV2 compared to HepG2CAT-pZeoSV2 cells (Fig. 3) also had functional consequences. In this context, it is proposed that HBxAg-positive hepatocytes, being relatively TGF-b1 resistant, would acquire a survival advantage over HBxAg-negative hepatocytes during chronic infection. This would promote the persistence of virus-infected cells in the face of ongoing immune responses, which would be important for the maintenance of the carrier state despite multiple bouts of CLD. This would also promote the accumulation of HBxAg-positive cells in carriers with CLD, which is an important early step in tumorigenesis (Koike et al., 1994; Ueda et al., 1995) . These observations would predict a strong correlation between HBxAg staining in the liver and severity of CLD, which has already been reported (Feitelson, 1999; Jin et al., 2001 ).
There are additional ramifications of increased TGF-b1 activity in HBxAg-positive liver cells. For example, TGF-b represents an important mediator of liver fibrosis (Czaja et al., 1989; Gressner & Bachem, 1995) by stimulating the synthesis of collagen, fibronectin (Ignotz & Massague, 1986) , hyaluronan and proteoglycan (Bachem et al., 1989) in hepatic stellate cells. TGF-b also inhibits matrix degradation, by reducing collagenase gene expression and plasmin synthesis (Rieder et al., 1993) , and by increasing the synthesis of metalloproteinase inhibitors (Edwards et al., 1987) . TGF-b staining in hepatocytes also correlates with the degree of liver fibrosis in man (Castilla et al., 1991; Nagy et al., 1991) and rats (Czaja et al., 1989; ArmendarizBorunda et al., 1990) . In addition, a 2 -M inhibits TGF-binduced collagen synthesis in human liver myofibroblasts (Tiggelman et al., 1997) , and reduces elevated matrix synthesis of cultured rat hepatic stellate cells (Schuftan & Bachem, 1999) . This suggests a 2 -M may have an antifibrogenic effect in vivo, which is blocked in chronic HBV infection by HBxAg.
Elevated TGF-b1 activity may be immunosuppressive (Teicher, 2001) . For example, in vitro experiments with peripheral blood mononuclear cells isolated from HBV carriers have shown that TGF-b1 treatment significantly inhibited HBV core antigen-stimulated proliferation, interferon-c production and core antigen-specific cytotoxic T-cell activity (Kamura et al., 1993) . Although TGF-b1 also suppresses anti-tumour immunity in other tumour types (Teicher, 2001) , it is not clear whether this occurs with HCC.
Although TGF-b1 signalling negatively regulates cell growth, the constitutive activation of other signalling pathways, such as those involving NF-kB, Akt/PI3K, c-Jun and Ras/Raf/MAPK, may block Smad-mediated growth inhibition and apoptosis, and instead promote cell survival, motility, migration and other features commonly associated with tumour cells (Akhurst, 2002) . In this context, HBxAg is known to stimulate most of these signalling pathways (Henkler & Koshy, 1996; Feitelson, 1999) , so that increased TGF-b1 expression in HBxAg-positive cells may result in autocrine and/or paracrine growth and survival signals to HBxAg-positive hepatocytes at the expense of uninfected cells. Akt/PI3K, for example, is stimulated by HBxAg, and is known to block TGF-b1 apoptosis in HBxAgpositive cells, but it also known to block a 2 -M transcription (Kortylewski et al., 2003) . NF-kB also blocks a 2 -M gene expression by blocking STAT3 binding (which stimulates a 2 -M expression) to the a 2 -M promoter (Bode et al., 2001) . Under these conditions, increased TGF-b1 production by HBxAg-positive compared to -negative HepG2 cells will only serve to further promote the growth and survival of HepG2X (but not HepG2CAT) cells, which is observed in this study. Hence, the shift in a 2 -M and TGF-b1 expression levels by HBxAg during chronic infection may be another pathway whereby HBxAg contributes to hepatocarcinogenesis on the molecular level.
